CA2345767A1 - Therapie visant a ameliorer la cognition - Google Patents

Therapie visant a ameliorer la cognition Download PDF

Info

Publication number
CA2345767A1
CA2345767A1 CA002345767A CA2345767A CA2345767A1 CA 2345767 A1 CA2345767 A1 CA 2345767A1 CA 002345767 A CA002345767 A CA 002345767A CA 2345767 A CA2345767 A CA 2345767A CA 2345767 A1 CA2345767 A1 CA 2345767A1
Authority
CA
Canada
Prior art keywords
atypical antipsychotic
patients suffering
acetylcholinesterase inhibitor
alzheimer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002345767A
Other languages
English (en)
Inventor
Paul Leonce Irma De Nijs
Wim Louis Julien Parys
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2345767A1 publication Critical patent/CA2345767A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Cette invention a trait à des compositions pharmaceutiques renfermant un excipient et, comme premier ingrédient actif, un agent antipsychotique atypique (I), ainsi que, comme second ingrédient actif, un inhibiteur de l'acétylcholinestérase (II), chacun sous des quantités produisant un effet thérapeutique bénéfique chez des patients atteints de psychose, de la maladie d'Alzheimer ou de démences connexes. Cet effet thérapeutique bénéfique peut être un effet de synergie sur le fonctionnement cognitif de patients atteints de la maladie d'Alzheimer ou de démences connexes, être prophylactique, évitant une dégradation ultérieure de la cognition chez ces patients, ou encore atténuant les réactions indésirables dues à l'action sur l'un des ingrédients actifs des autres ingrédients actifs.
CA002345767A 1998-10-16 1999-10-12 Therapie visant a ameliorer la cognition Abandoned CA2345767A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98203454 1998-10-16
EP98203454.8 1998-10-16
PCT/EP1999/007804 WO2000023057A2 (fr) 1998-10-16 1999-10-12 Therapie visant a ameliorer la cognition

Publications (1)

Publication Number Publication Date
CA2345767A1 true CA2345767A1 (fr) 2000-04-27

Family

ID=8234219

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002345767A Abandoned CA2345767A1 (fr) 1998-10-16 1999-10-12 Therapie visant a ameliorer la cognition

Country Status (20)

Country Link
EP (1) EP1121131A2 (fr)
JP (1) JP2002527469A (fr)
KR (1) KR20010072878A (fr)
CN (1) CN1367697A (fr)
AU (1) AU6472799A (fr)
BG (1) BG105302A (fr)
BR (1) BR9914419A (fr)
CA (1) CA2345767A1 (fr)
EE (1) EE200100136A (fr)
HK (1) HK1039745A1 (fr)
HR (1) HRP20010262A2 (fr)
HU (1) HUP0103781A3 (fr)
ID (1) ID28441A (fr)
IL (1) IL142588A0 (fr)
NO (1) NO20011403L (fr)
PL (1) PL348107A1 (fr)
SK (1) SK4592001A3 (fr)
TR (1) TR200101082T2 (fr)
WO (1) WO2000023057A2 (fr)
ZA (1) ZA200103081B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
DE60238780D1 (de) * 2001-10-30 2011-02-10 Novartis Ag Depot formulierungen von iloperidone und einem sternförmigen polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
EP1824848A1 (fr) * 2004-12-10 2007-08-29 Abbott Laboratories Derives polycycliques de quinuclidine substitues par un bicycloheterocycle condense
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
EP2117540A1 (fr) 2007-03-01 2009-11-18 Probiodrug AG Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
MX2007008642A (es) * 2007-07-16 2009-02-25 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias.
EP2533645B1 (fr) 2010-02-09 2016-07-27 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
EP2919788A4 (fr) 2012-11-14 2016-05-25 Univ Johns Hopkins Méthodes et compositions pour le traitement de la schizophrénie
EP2968237A4 (fr) 2013-03-15 2016-08-31 Univ Johns Hopkins Procédés et compositions pour améliorer la fonction cognitive
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0584185T3 (da) * 1991-05-14 2000-02-07 Ernir Snorrason Behandling af træthedssyndrom med cholinesteraseinhibitorer
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DK1011678T3 (da) * 1997-08-11 2008-05-05 Univ South Florida Anvendelse af mecamylamin til behandling af nikotin-responsive neuropsykiatriske lidelser
IL139008A0 (en) * 1998-04-14 2001-11-25 Gen Hospital Corp Methods for treating neuropsychiatric disorders

Also Published As

Publication number Publication date
ID28441A (id) 2001-05-24
AU6472799A (en) 2000-05-08
ZA200103081B (en) 2002-07-12
HRP20010262A2 (en) 2002-06-30
NO20011403D0 (no) 2001-03-20
SK4592001A3 (en) 2001-12-03
CN1367697A (zh) 2002-09-04
KR20010072878A (ko) 2001-07-31
HUP0103781A3 (en) 2003-09-29
BG105302A (en) 2001-11-30
EE200100136A (et) 2002-06-17
HUP0103781A2 (hu) 2002-03-28
NO20011403L (no) 2001-03-20
JP2002527469A (ja) 2002-08-27
EP1121131A2 (fr) 2001-08-08
HK1039745A1 (zh) 2002-05-10
TR200101082T2 (tr) 2001-09-21
WO2000023057A2 (fr) 2000-04-27
WO2000023057A3 (fr) 2000-07-27
IL142588A0 (en) 2002-03-10
PL348107A1 (en) 2002-05-06
BR9914419A (pt) 2001-06-26

Similar Documents

Publication Publication Date Title
CA2345767A1 (fr) Therapie visant a ameliorer la cognition
RU93004484A (ru) Производные пиразола, способ их получения и содержащие их фармацевтические композиции
EP1350511B1 (fr) Compositions medicales contenant de l'aspirine
RU2212886C2 (ru) КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ И ПРЕДОТВРАЩЕНИЯ АРТЕРИАЛЬНОГО ТРОМБОЗА И ПРИМЕНЕНИЕ ИНГИБИТОРА ФАКТОРА Ха САМОГО ПО СЕБЕ И/ИЛИ В КОМБИНАЦИИ С АГЕНТОМ, ПРЕПЯТСТВУЮЩИМ АГРЕГАЦИИ ТРОМБОЦИТОВ
YU66600A (sh) Farmaceutski preparati koji mogu da budu gelirani
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
US6291471B1 (en) Use of apomorphine for the treatment of organic erectile dysfunction in males
JP2001523715A (ja) 脂肪酸のコリンエステル及び脳卒中の治療におけるそれらの使用
MD1699F2 (ro) Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei
CA2433585A1 (fr) Compositions pharmaceutiques contenant du chlorhydrate de donepezil
ATE224712T1 (de) Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen
JP2019510039A5 (fr)
CA2378613A1 (fr) Antagonistes selectifs du recepteur iglur5 utilises dans le traitement de la migraine
JP2019501861A (ja) 水不溶性またはわずかに水溶性の薬剤の水可溶性を改善するための方法
CN1317030C (zh) 用中等剂量的lhrh拮抗剂治疗阿尔茨海默氏病
HUT61743A (en) Process for producing 2-(piperidin-1-yl)-ethanol derivatives and pharmaceutical compositions comprising such compounds as active ingredient
KR20060130619A (ko) 유기 화합물의 조합물
HUP0102987A3 (en) Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient
JP4135263B2 (ja) クリーム状洗浄剤組成物
JPH04217915A (ja) ４−エチル−２−ヒドロキシイミノ−５−ニトロ−３−ヘキセンアミド含有製剤用の安定化剤、安定化方法及び安定化された製剤
EP0671908B1 (fr) Compositions pharmaceutiques comprenant des agonistes des recepteurs 5-ht 1? et des stimulateurs d'absorption
CA1209047A (fr) Compose therapeutique contenant un analogue du piracetam
NZ321370A (en) Polymorphic forms of a growth hormone secretagogue
WO2001093832A3 (fr) Compositions aqueuses de protection des cartilages présentant des contraintes posologiques déterminées pour une administration efficace
RU2001113270A (ru) Лечение, направленное на улучшение познавательной способности

Legal Events

Date Code Title Description
FZDE Discontinued